Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

Publisher Name :
Date: 15-Sep-2016
No. of pages: 145
Inquire Before Buying

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market.

The global cancer immunotherapy market has been segmented on the basis of type, application, enduser, and region. The monoclonal antibodies segment is expected to register the highest growth rate in the cancer immunotherapy market, by type, during the forecast period. Factors such as high success rate and less recovery time are contributing to the high growth in this segment.

Based on application, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others (renal cell carcinoma, cervical, gastric, and lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2016 to 2021, primarily due to the rising prevalence of this type of cancer.

Based on endusers, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of drugs in hospitals.

Geographically, the cancer immunotherapy market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of North America can be attributed to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity.

Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output, in order to remain successful in the cancer immunotherapy market.

The major players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F.Hoffman La-RocheLtd. (Switzerland), BayerAG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

Objectives Of The Study


  • To define, describe, and forecast the global cancer immunotherapy market on the basis of type, application, end user, and region

  • To provide detailed information regarding the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the global cancer immunotherapy market

  • To strategically analyze the markets with respect to their individual growth trends, future prospects, and contributions to the total market

  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

  • To forecast the revenue of market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)

  • To profile the key players and comprehensively analyze their market shares and core competencies

  • To analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and R&D activities in the global cancer immunotherapy market


Target Audience for this Report:


  • Drug Manufacturers and Suppliers

  • Academic Research Institutes

  • Hospitals and Clinics

  • Research and Development (R&D) Companies

  • Business Research and Consulting Service Providers

  • Medical Research Laboratories

  • Academic Medical Centers and Universities


Scope of the Report:

In this report, the cancer immunotherapy market has been segmented into the following segments and subsegments:

Cancer Immunotherapy Market, by Type


  • Monoclonal Antibodies

  • Cancer Vaccines

  • Checkpoint Inhibitors

  • Immunomodulators


Cancer Immunotherapy Market, by Application


  • Lung Cancer

  • Breast Cancer

  • Head and Neck Cancer

  • Prostate Cancer

  • Colorectal Cancer

  • Melanoma

  • Others


Cancer Immunotherapy Market, by End User


  • Hospitals

  • Clinics & Others


Cancer Immunotherapy Market, by Region


  • North America

    • U.S.

    • Canada



  • Europe

    • Germany

    • France

    • Italy

    • U.K.

    • Spain

    • RoE



  • APAC

    • India

    • China

    • Japan

    • RoAPAC



  • Rest of the World (RoW)

    • South America, Central America, and the Caribbean

    • Oceania

    • Africa



Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

Table of Contents

1 Introduction
1.1 Objectives of the Study
1.2 Cancer Immunotherapy Market Definition
1.3 Markets Covered
1.3.1 Years Considered for the Study
1.4 Currency
1.5 Stakeholders

2 Research Methodology
2.1 Cancer Immunotherapy Market Size Estimation
2.2 Cancer Immunotherapy Market Breakdown and Data Triangulation
2.3 Cancer Immunotherapy Market Share Estimation
2.3.1 Key Data From Secondary Sources
2.3.2 Key Data From Primary Sources
2.4 Assumptions for the Study

3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook

4 Premium Insights
4.1 Lucrative Opportunities in the Cancer Immunotherapy Market

5 Market Overview
5.1 Introduction
5.1.1 Drivers
5.1.1.1 Rise in Incidence Rate of Cancer Worldwide
5.1.1.2 Increase in Adoption of Immunotherapy Over Other Treatment Options
5.1.1.3 Development of Bioinformatics Tools are Enhancing Drug Development Process
5.1.2 Restraints
5.1.2.1 High Cost of Treatment
5.1.3 Opportunities
5.1.3.1 Increase in Clinical Trials Against Several Types of Cancers in Immunotherapy
5.1.3.2 High Growth Projections in the Developing Countries
5.1.4 Challenges
5.1.4.1 Availability of Limited Funds to Initiate Clinical Trials
5.1.4.2 Complexity of Cancer May Limit the Immune Response
5.2 Overview of Global Cancer Immunotherapy Funding

6 Industry Trends
6.1 Global Trends in Cancer Immunotherapy Market
6.1.1 Opdivo (Niolumab) and Keytruda (Pembrolizumab) Fda Approval in U.S. Increases Hope Amongst Lung Cancer Patients
6.1.2 Combination Immunotherapy Potential Way to Treat Melanoma
6.1.3 U.S. Cancer Immunotherapy Research Community Builds Hope to Combat Cancer By 2020
6.1.4 U.K. Scientists Project A Change in the Means of Treatment for Cancer With Quality Therapies
6.1.5 World is Moving Toward Personalized Immunotherapy
6.1.6 A Combination of Modern Immunotherapy and Traditional Chinese Medicines Continues to Increase Survival Rate of Patients in China
6.2 Pricing Variations in Global Cancer Immunotherapy Market
6.3 Small Players Getting Together to Make Long Term Impact in Cancer Immunotherapy Market
6.4 Attractions for Pharmaceutical Industry
6.5 Heat Map for Variations in Cancer Immunotherapy for Different Types of Cancers
6.5.1 Breast Cancer
6.5.2 Lung Cancer
6.5.3 Multiple Myeloma
6.5.4 Lymphoma

7 Cancer Immunotherapy Market, By Product Type
7.1 Introduction
7.2 Monoclonal Antibodies
7.2.1 Naked Monoclonal Antibodies
7.2.2 Conjugated Monoclonal Antibodies
7.2.3 Bispecific Monoclonal Antibodies
7.3 Vaccines
7.3.1 Prophylactic Vaccines
7.3.2 Therapeutic Vaccines
7.4 Check Point Inhibitors
7.4.1 Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
7.4.2 Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1)
7.5 Cell Therapies
7.5.1 Chimeric Antigen Receptor (CAR) T Cell Therapy
7.5.2 Dendritic Cells
7.6 Immunomodulators
7.6.1 Granulocyte/Macrophage Colony-Stimulating Factor  (GM-CSF & G-CSF)
7.6.2 Interferons (IFN)
7.6.3 Interleukins (IL)
7.6.4 Oncolytic Virus
7.6.4.1 Immunotherapy
7.6.4.1 Immunity as an Obstacle
7.6.4.2 Immunity as an Ally
7.6.4.3 Approved Products & Clinical Trails

8 Cancer Immunotherapy Market, By Application
8.1 Introduction
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Multiple Myeloma
8.5 Colorectal Cancer
8.6 Head & Neck Cancer
8.7 Prostate Cancer
8.8 Melanoma
8.9 Other Cancer Types

9 Cancer Immunotherapy Market, By End User
9.1 Introduction
9.2 Hospital
9.3 Clinics and Others

10 Cancer Immunotherapy Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia-Pacific
10.5 Rest of the World (RoW)

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis
11.3 Competitive Situation and Trends
11.3.1 Approvals
11.3.2 Agreements, Partnerships, and Collaborations
11.3.3 Acquisitions
11.3.4 Expansions
11.3.5 Other Developments

12 Company Profile
(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
12.1 Amgen Inc.
12.2 Astrazeneca
12.3 Bayer AG
12.4 Bristol-Myers Squibb
12.5 Eli Lilly and Company
12.6 Janssen Global Services, LLC (Johnson and Johnson)
12.7 Merck
12.8 Novartis
12.9 Pfizer
12.10 F. Hoffmann-LA Roche Ltd

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View Might Not Be Captured in Case of Unlisted Companies.

13 Appendix
13.1 Insights From Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT : Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports

List of Tables

Table 1 Overview of Funding Pattern in Different Types of Cancer By Nih, U.S., 2012–2017 (USD Million)
Table 2 Overview of Key Funding in Cancer Immunotherapy Market, 2016
Table 3 Conventional Cancer Therapy Versus Cancer Immunotherapy
Table 4 Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 5 Cancer Monoclonal Antibodies Market Size, By Subtype, 2014–2021 (USD Million)
Table 6 Cancer Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 7 Naked Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 8 Conjugated Monoclonal Antibodies Market, By Region, 2014–2021 (USD Million)
Table 9 Bispecific Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Million)
Table 10 Vaccines Market, By Subtype, 2014–2021 (USD Million)
Table 11 Vaccines Market, By Region, 2014–2021 (USD Million)
Table 12 Prophylactic Vaccines Market Size, 2014–2021 (USD Million)
Table 13 Therapeutic Vaccines Market, By Region, 2014–2021 (USD Million)
Table 14 Checkpoint Inhibitors Market Size, By Subtype, 2014–2021 (USD Million)
Table 15 Checkpoint Inhibitors Market, By Region, 2014–2021 (USD Million)
Table 16 Cytoxic T-Lymphocyte Market Size, By Region, 2014–2021 (USD Million)
Table 17 Cytoxic T-Lymphocyte Market Size, By Region, 2014–2021 (USD Million)
Table 18 Immunomodulators Market Size, By Subtype, 2014–2021 (USD Million)
Table 19 Immunomodulators Market Size, By Region, 2014–2021 (USD Million)
Table 20 Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF) Market Size, By Region, 2014–2021 (USD Million)
Table 21 Interferons Market Size, By Region, 2014–2021 (USD Million)
Table 22 Interleukins Market Size, By Region, 2014–2021 (USD Million)
Table 23 Cancer Immunotherapy Market Size, By Application, 2014–2021 (USD Million)
Table 24 Lung Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 25 Breast Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 26 Multiple Myeloma Market Size, By Region, 2014–2021 (USD Million)
Table 27 Colorectal Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 28 Head & Neck Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 29 Prostate Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 30 Melanoma Market Size, By Region, 2014–2021 (USD Million)
Table 31 Other Types of Cancer Market Size, By Region, 2014–2021 (USD Million)
Table 32 Cancer Immunotherapy Market Size, By End User, 2014–2021 (USD Million)
Table 33 Hospitals Market Size, By Region, 2014–2021 (USD Million)
Table 34 Clinics and Others Market Size, By Region, 2014–2021 (USD Million)
Table 35 Cancer Immunotherapy Market Size, By Region, 2014–2021 (USD Million)
Table 36 North America: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 37 Europe: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 38 Asia-Pacific: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 39 RoW: Cancer Immunotherapy Market Size, By Product Type, 2014–2021 (USD Million)
Table 40 Approvals, 2013–2016
Table 41 Agreements, Partnerships, and Collaborations, 2013–2016
Table 42 Acquisitions, 2013–2016
Table 43 Expansions, 2013–2016

List of Figures

Figure 1 Classification of Cancer Immunotherapy
Figure 2 Research Design
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 The Monoclonal Antibody Segment is Expected to Lead the Global Cancer Immunotherapy Market During the Forecast Period
Figure 8 The Lung Cancer Segment to Lead the Global Cancer Immunotherapy Market in 2016
Figure 9 Hospitals are Major End Users of the Global Cancer Immunotherapy Market
Figure 10 North America Led the Global Cancer Immunotherapy Market in 2015
Figure 11 Future of Cancer Immunotherapeutics
Figure 12 Global Cancer Immunotherapy Market to Witness High Growth During the Forecast Period
Figure 13 Lung Cancer Application Dominated the Global Cancer Immunotherapy Market, 2016
Figure 14 Asia-Pacific to Witness the Fastest Growth During the Forecast Period
Figure 15 Lung Cancer to Witness the Fastest Growth During the Forecast Period in the Cancer Immunotherapy Market
Figure 16 Drivers, Restraints, Opportunities, and Challenges
Figure 17 Population Forecasts for All Cancers Excluding Non-Melanoma Skin Cancer, 2012 vs 2020
Figure 18 Pricing Trend of Imbruvica Across Major Pharmaceutical Market in 2016
Figure 19 Heat Map Showing Variations in Immunotherapy Drugs Used for Breast Cancer
Figure 20 Annual Cost of Breast Cancer Immunotherapy, 2016
Figure 21 Heat Map Showing Variations in Immunotherapy Drugs Used for Lung Cancer
Figure 22 Annual Cost of Lung Cancer Immunotherapy, 2016
Figure 23 Heat Map Showing Variations in Immunotherapy Drugs Used for Multiple Myeloma
Figure 24 Annual Cost of Multiple Myeloma Immunotherapy, 2016
Figure 25 Heat Map Showing Variations in Immunotherapy Drugs Used for Lymphoma
Figure 26 Annual Cost of Lymphoma Immunotherapy, 2016
Figure 27 Cancer Immunotherapy Market Size, By Product Type
Figure 28 Monoclonal Antibodies Segment to Dominate the Cancer Immunotherapy Market Size in 2016
Figure 29 Naked Monoclonal Antibodies to Account for the Largest Share in 2016
Figure 30 North America to Account for the Largest Share of the Cancer Monoclonal Antibodies Market in 2016
Figure 31 Vaccines Market Size, By Subtype, 2016–2021 (USD Million)
Figure 32 Asia-Pacific Expected to Be the Fastest-Growing Regional Segment of the Vaccines Market
Figure 33 Programmed Death 1(PD-1) is Expected to Be the Fastest-Growing Segment of the Check Point Inhibitors Market
Figure 34 RoW is Expected to Account the Fastest-Growing Regional Segment of the Checkpoint Inhibitors Market
Figure 35 GM-CSF & G-CSF Segment is Expected to Dominate the Immunomodulators Market in 2016
Figure 36 North America is Expected to Account for the Largest Share in the Immunomodulators Market Through 2021
Figure 37 Cancer Immunotherapy Market, By Application
Figure 38 Lung Cancer Segment Leads the Cancer Immunotherapy Market Size in 2016
Figure 39 North America Accounts for the Largest Share of the Lung Cancer Immunotherapy Market in 2016
Figure 40 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Breast Cancer in 2016
Figure 41 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Multiple Myeloma in 2016
Figure 42 North America Accounts for the Largest Share of the Cancer Immunotherapy Market for Colorectal Cancer in 2016
Figure 43 North America Estimated to Account for the Largest Share of the Immunotherapy Market for Head & Neck Cancer in 2016
Figure 44 North America Estimated to Dominate the Immunotherapy Market for Prostate Cancer in 2016
Figure 45 North America is Projected to Be the Fastest-Growing Region in the Cancer Immunotherapy Market for Melanoma During the Forecast Period
Figure 46 Asia-Pacific is Projected to Be the Fastest-Growing Region in the Immunotherapy Market for Other Cancer Types, 2016-2021
Figure 47 Cancer Immunotherapy Market, By End User, 2016 vs 2021 (USD Million)
Figure 48 Hospitals Market Size, 2016 vs 2021, By Region (USD Million)
Figure 49 Clinics and Others Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 50 Geographic Snapshot: Asia-Pacific is Projected to Be the Fastest-Growing Region During the Forecast Period
Figure 51 Checkpoint Inhibitors Segment is Projected to Grow at the Highest Rate From 2016 to 2021
Figure 52 North America: Cancer Immunotherapy Market Snapshot, 2016
Figure 53 The Check Point Inhibitors is Projected to Be the Fastest-Growing Market in North America During the Forecast Period
Figure 54 Monoclonal Antibodies Segment is Projected to Dominate the Cancer Immunotherapy Market in Europe Till 2021
Figure 55 Asia-Pacific: Cancer Immunotherapy Market Snapshot, 2016
Figure 56 Checkpoint Inhibitors Segment is Expected to Lead the Cancer Immunotherapy Market in the RoW Region Till 2021
Figure 57 Companies Adopted Approvals as Their Key Growth Strategy Over the Last Three Years
Figure 58 Global Cancer Immunotherapy Market Share, By Key Player, 2015
Figure 59 Approvals: the Key Growth Strategy Adopted By Market Players From 2013 to 2015
Figure 60 Amgen: Company Snapshot
Figure 61 Astrazeneca: Company Snapshot
Figure 62 Bayer AG: Company Snapshot
Figure 63 Bristol-Myers Squibb: Company Snapshot
Figure 64 Eli Lilly and Company: Company Snapshot
Figure 65 Janssen Global Services, LLC: Company Snapshot
Figure 66 Merck: Company Snapshot
Figure 67 Novartis; Company Snapshot
Figure 68 Pfizer : Company Snapshot
Figure 69 F. Hoffmann-LA Roche Ltd.: Company Snapshot

  • United States Non-small Cell Lung Cancer Therapeutics Market Report 2016
    Published: 01-Dec-2016        Price: US 3800 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Non-small Cell Lung Cancer Therapeutics Revenue, means the sales value of Non-small Cell Lung Cancer Therapeutics This report studies sales (consumption) of Non-small Cell Lung Cancer Therapeutics in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Bristol-Myers Squibb - GlaxoSmithKline - Menarini - Sanofi - ZIOPHARM Onco......
  • Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 477
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfo......
  • Small-Cell Lung Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 588
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spr......
  • Gallbladder Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 74
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts......
  • Vaginal Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 68
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2016, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment include......
  • Epithelial Ovarian Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 507
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epithelial Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Epithelial Ovarian Cancer (Oncology) pipeline landscape.Ovarian epithelial cancer is a disease in which malignant (cancer) cells form in the tissue covering the ovary. Early ovarian cancer may not cause any symptoms. When symptoms do appear, ovarian cancer is often advanced. Symptoms may include pain or swelling in the abdomen, p......
  • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 463
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer (Oncology) pipeline landscape.Metastatic hormone refractory prostate cancer (mHRPC), also known as metastatic androgen independent prostate cancer or metastatic castrate-resis......
  • Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 108
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsen......
  • Follicular Lymphoma - Pipeline Review, H2 2016
    Published: 30-Nov-2016        Price: US 2000 Onwards        Pages: 540
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Follicular Lymphoma - Pipeline Review, H2 2016, provides an overview of the Follicular Lymphoma (Oncology) pipeline landscape.Follicular lymphoma is a common type of non-Hodgkin Lymphoma (NHL). It is a slow-growing lymphoma that arises from B-cells, a type of white blood cell. It is also called an "indolent" or "low-grade" lymphoma for its slow nature. Follicular lymphoma mainly affects older adults. Enlargeme......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs